US 12,246,302 B2
Blood treatment material
Kyohei Yamashita, Otsu (JP); Shungo Kanda, Otsu (JP); and Hiroshi Takahashi, Otsu (JP)
Assigned to Toray Industries, Inc., Tokyo (JP)
Appl. No. 17/764,436
Filed by Toray Industries, Inc., Tokyo (JP)
PCT Filed Oct. 2, 2020, PCT No. PCT/JP2020/037573
§ 371(c)(1), (2) Date Mar. 28, 2022,
PCT Pub. No. WO2021/066152, PCT Pub. Date Apr. 8, 2021.
Claims priority of application No. 2019-183381 (JP), filed on Oct. 4, 2019.
Prior Publication US 2022/0362742 A1, Nov. 17, 2022
Int. Cl. B01J 20/26 (2006.01); B01D 15/08 (2006.01); B01J 20/28 (2006.01); B01J 20/289 (2006.01); B01J 20/32 (2006.01)
CPC B01J 20/265 (2013.01) [B01D 15/08 (2013.01); B01J 20/28011 (2013.01); B01J 20/28023 (2013.01); B01J 20/289 (2013.01); B01J 20/321 (2013.01); B01J 20/3219 (2013.01); B01J 20/3257 (2013.01); B01J 20/3295 (2013.01); B01J 2220/52 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A blood treatment material comprising a water-insoluble material in the form of fibers or particles, wherein a difference between a maximum value (RaA) and a minimum value (RaB) of a arithmetic average roughness (Ra) of a surface of said water-insoluble material, as calculated using a laser microscope, is 0.30 to 1.50 μm;
wherein said water-insoluble material is in the form of fibers; and
a direction of measurement of said laser microscope in which said arithmetic average roughness (Ra) of the surface of said water-insoluble material is minimum, is a fiber longitudinal direction.